Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma  >>  Phase 2
Welcome,         Profile    Billing    Logout  

8 Trials

   Remove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
NCT04217317: CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma

Recruiting
2
12
US
CPI 613, devimistat, Bendamustine, Bendeka, Treanda, Bendamustine Hydrochloride
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma, Non Hodgkin Lymphoma
11/24
06/25
NCT05854966: CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Not yet recruiting
2
17
US
CPI 613, Devimistat, Metformin, Metformin pill, Blood draws, Bone marrow biopsy
Wake Forest University Health Sciences, National Cancer Institute (NCI), Cornerstone Pharmaceuticals
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma
04/25
09/25
NCT03793140: A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

Active, not recruiting
2
24
US
CPI-613
Memorial Sloan Kettering Cancer Center, City of Hope Medical Center, Massachusetts General Hospital, M.D. Anderson Cancer Center, George Washington University
Lymphoma, Leukemia
12/24
12/24
NCT05733000: CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Recruiting
2
94
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Devimistat, Alpha-Lipoic Acid Analogue CPI-613, CPI 613, CPI-613, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, FF 10832, FF-10832, FF10832, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Hydroxychloroquine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging
Northwestern University, National Cancer Institute (NCI)
Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Urothelial Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Urothelial Carcinoma, Refractory Biliary Tract Carcinoma, Refractory Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Urothelial Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
01/28
03/30
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
NCT03699319: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Active, not recruiting
1/2
49
US
CPI 613, 6, 8-bis-benzylsulfanyloctanoic acid, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, 5-flurouracil, 5FU, Folinic acid, Leucovorin, Calcium folinate, FA
David Bajor
Pancreatic Cancer
09/24
09/24
BilT-04, NCT04203160: Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer

Active, not recruiting
1/2
75
US
CPI 613, Devimistat®, Gemcitabine, Gemzar®, Cisplatin, CDDP, Platinol®, NSC-119875
University of Michigan Rogel Cancer Center
Biliary Tract Cancer
04/24
05/25
NCT05926206: Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas

Withdrawn
1/2
60
US
Devimistat, Modified FOLFIRINOX
University of Michigan Rogel Cancer Center
Metastatic Pancreatic Adenocarcinoma
01/27
01/27

Download Options